Chief Executive Officer
Moshe Landsberg has 20 years of executive level experience in the development, manufacture and commercialization of bio-pharm and medical products. Prior to joining EnzySurge, he held the position of VP Technology & QA of BioCancell Therapeutics Ltd - a public company (TASE) that develops patient oriented, targeted therapy for the treatment of different solid cancer tumors. He also held executive positions in several Medical Device companies, such as the COO at BioPreventative Ltd (later Analyte Works Ltd), QA director at Common Sense Ltd and QA and Operations Manager at Lithotech Medical Ltd. In his 17 years at Biotechnology General (Israel) Ltd, he progressed from Fermentation and Crude Process Department Manager to the senior position of Special Projects Manager.
Mr. Landsberg holds an MSc degree in applied Microbiology from the Hebrew University of Jerusalem and BSc in Life Sciences from the Tel-Aviv University. He currently lectures at the Agriculture Faculty of the Hebrew University as well as at the BioForum Applied Knowledge Center.close
Noa Hadar, PhD
Dr. Hadar brings to EnzySurge 12 years of experience in R&D in the fields of Bio Catalysis, Biochemistry, Nano Biotechnology and wound healing. In the past three years Dr. Hadar headed up the development of two EnzySurge products - therapeutic solutions for wound debridement and wound management - successfully culminating in formulation development, adaptation of analytical methods, storage stability studies and shift from the bench to industrial scale production plus R&D coordination with regulatory and reimbursement requirements.
Dr. Hadar holds a BSc degree in Biotechnology and Chemical Engineering, MSc in Biotechnology (applied bio catalysis) and PhD in Nano Biotechnology. She has authored and published 9 papers in referred journals and has registered two patents.close
VP Marketing & Sales
Gad Bar-Sela, who holds an MSc degree in Organic Chemistry from the Weizmann Institute in Israel, has over 30 years of experience in the sales and marketing of industrial systems and medical devices. Former VP Marketing & Sales at CommonSense Ltd - developer and producer of women’s health diagnostic devices, Business Development consultant at Meytav Technological Accelerator, CEO at MTRE - producer and developer of thermo-regulation medical devices, and VP Marketing & Sales at Elbit Vision Systems (EVS) Ltd - the world leader in automatic vision web inspection systems.close
Director of Finance
Shai Avnit, C.P.A., has extensive experience in managing financial, operational, administrative and legal affairs in companies within the medical device, consumer electronics and software fields. He served as C.F.O. and other leading financial positions in several hi-tech companies, both public and private. He holds a B.A. in Accounting & Economics as well as an M.B.A. majoring in Finance & Marketing, both from Tel Aviv University.close
Eitan brings to EnzySurge more than 30 years of comprehensive and rich experience in Quality Management in the Hi-tech industry, of which more than 2 decades were in the medical device arena in various companies, including GE Healthcare, Lumenis & Elbit.Eitan holds a B.A. degree from Derby University and a CQE (Certified Quality Engineer) diploma from the American Society for Quality Control (ASCQ) and the Israeli Quality Society.
Elinor Salzberger, BSc.
Engineering and Product Manager
Elinor joined EnzySurge at the beginning of 2017. During the last year, Elinor is heading the development of the new SilverStream Gel product for human and veterinary wound management. Elinor's responsibility includes formulation development, analytical methods, stability studies and packaging requirements.
Elinor holds a BSc degree in Biomedical Engineering from Tel-Aviv University.close
Daniel Albahari MSc, RAC.
Regulatory affairs professional
Daniel is a regulatory affairs professional specializing in regulatory strategy, medical device and combination product submissions and in commercializing new products and technologies.
During his academic career, Daniel received the prestigious Boehringer Ingelheim Fonds Research Award as well as other professional recognitions. He has lectured on various regulatory topics in Israel and abroad.
Daniel has provided regulatory affairs services to many private and public companies in Israel, the EU and USA. He has undertaken substantial regulatory work in recent years for an impressive range of companies including Abic Teva, BiolineRx, Izun Pharma, Rekah Pharmaceuticals, Silenseed, Wize Pharma, Mileutis, Yissum Agritech of the Hebrew University of Jerusalem, among many others.
Daniel holds an MSc degree in Molecular Biochemistry and Genetics and a RAC (US-Regulatory Affairs) degree.close